Release Details
Webcast Alert: Isis Pharmaceuticals Announces Its Analyst/Investor Webcast Presentation
CARLSBAD, Calif., Nov. 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals (Nasdaq: ISIS) announces the following webcast:
What: Isis Pharmaceuticals' analyst/investor presentation
highlighting new Phase 2 clinical data from ISIS 301012
studies planned for release at the American Heart Association
Scientific Sessions. ISIS 301012 is the Company's
cholesterol-lowering drug targeting apoB-100.
When: November 13, 2006 @ 8:00 AM Eastern
Where: www.isispharm.com
How: Live over the Internet -- select the link on Isis' home page
at the address above.
Contact: Kate Corcoran, Ph.D.
Vice President, Corporate Development
760-603-2712
If you are unable to participate during the live webcast, the presentation will be available for replay at www.isispharm.com.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 14 drugs in development. Isis' drug development programs are aimed at treating cardiovascular, metabolic and inflammatory diseases. Isis' partners are focused in disease areas such as ocular, viral and neurodegenerative diseases, and cancer. In its Ibis Biosciences division, Isis is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of approximately 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.
SOURCE Isis Pharmaceuticals
11/09/2006
CONTACT: Kate Corcoran, Ph.D., Vice President, Corporate Development of
Isis Pharmaceuticals, +1-760-603-2712